The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1) monoclonal antibody, (Secukinumab, Cosentyx) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune related adverse event (colitis, hepatitis, skin rash, psoriatic arthritis) to ICI, and are re-initiating ICI therapy.